Dual HIV infection has been found in regions with high HIV prevalence and in populations infected with diverse strains of HIV. The prevalence of dual infection in KwaZulu-Natal (KZN), where there is a high prevalence of HIV and an influx of immigrants who may be infected with different HIV subtypes, is unknown. The aim of this study was to determine the prevalence of dual infection in KZN. Eighty-three samples were obtained from chronically infected patients on ARV treatment from sites throughout KZN. Subtyping of the samples was performed using the heteroduplex mobility assay (HMA). Twelve samples that had possible dual infection by HMA were cloned and sequenced. Phylogenetic analysis showed that there was no dual infection in these samples. Contrary to a previous study, we did not find dual infection in this region. The patients in our study may be different from those in the previous study in terms of transmission risk factors, treatment, and stage of infection (acute vs. chronic). This study may have important implications for vaccine development and for the pathogenesis and treatment of dual HIV infection.
Get full access to this article
View all access options for this article.
References
1.
PerelsonA, NeumannA, MarkowitzM, LeonardJ, HoD. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science, New Series, 1996; 271:1582–1586.
2.
RobertsJ, KatarzynaB, KunkelT. The accuracy of reverse transcriptase from HIV-1. Science, New Series, 1988; 242:1171–1173.
3.
PulsinelliG, TeminH. High rate of mismatch extension during reverse transcription in a single round of retrovirus replication. Genetics, 1994; 91:9490–9494.
4.
BattulaN, LoebL. On the fidelity of DNA replication: Lack of exodeoxyribonuclease activity and error-correcting function in avian myeloblastosis virus DNA polymerase. J Biol Chem, 1976; 251,4:982–986.
ThomsonM, DelgadoE, HerreroIet al.Diversity of mosaic structures and common ancestry of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Argentina revealed by analysis of near full-length genome sequences. J Gen Virol, 2002; 83:107–119.
8.
DowlingW, KimB, MasonCet al.Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. AIDS Patient Care STDS, 2002; 16:1809–1820.
9.
ThomsonM, Pérez-ÁlvarezL, NájeraR. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis, 2002; 2:461–471.
10.
CarrJ, ÁvilaM, CarrilloMet al.Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS, 2001; 15:F41–F47.
11.
YangR, XiaX, KusagawaS, ZhangC, BenK, TakebeY. On-going generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan Province of China. AIDS, 2002; 16:1401–1407.
BlackardJT, CohenDE, MayerKH. Human immunodeficiency virus superinfection and recombination: Current state of knowledge and potential clinical consequences. Clin Infect Dis, 2002; 34:1108–1114.
14.
HerbingerKH, GerhardtM, PiyasirisilpSet al.Frequency of HIV type 1 dual infection and HIV diversity: Analysis of low- and high-risk populations in Mbeya Region, Tanzania. AIDS Res Hum Retroviruses, 2006; 22:599–606.
15.
SteainM, WangB, YangCet al.HIV type 1 sequence diversity and dual infections in Kenya. AIDS Res Hum Retroviruses, 2005; 21:882–885.
16.
RamosA, TanuriA, SchechterMet al.Dual and recombinant infections: An integral part of the HIV-1 epidemic in Brazil. Emerg Infect Dis, 1999; 5:65–74.
17.
GroblerJ, GrayCM, RademeyerCet al.Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis, 2004; 190:1355–1359.
18.
BrennerB, RoutyJ-P, QuanYet al.Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS, 2004; 18:1653–1660.
19.
SmithD, WongaJ, HightowerGet al.HIV drug resistance acquired through superinfection. AIDS Patient Care STDS, 2005; 19:1251–1256.
20.
National HIV and syphilis antenatal seroprevalence survey in South Africa 2005. HealthDo. 2006.
21.
QuinnTC. Population migration and the spread of types 1 and 2 human immunodeficiency viruses. Proc Natl Acad Sci USA, 1994; 91:2407–2414.
22.
WHO. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. World Health Organization: Geneva, Switzerlandhttp://www.who.int/hiv/pub/guidelines/WHO%20HIV%20Staging.pdf2006.
23.
BoomR, SolC, SalimansM, JansenC, Wertheim-vanDillen P, van der NoordaaJ. Rapid, simple method for purification of nucleic acids. J Clin Microbiol, 1990; 28:495–503.
24.
ThompsonJ, HigginsD, GibsonTJ. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res, 1994; 22:4673–4680.
25.
SmithS, OverbeekR, WoeseC, GilbertW, GilbertPM. The Genetic Data Environment: An expandable GUI for multiple sequence analysis. Comput Appl Sci, 1994; 10:671–675.
26.
SwoffordK. PAUP 4.0: Phylogenetic Analysis with Parsimony (and Other Methods)Sinauer Associates: Sunderland, MA, 1999.
27.
PosadaD, CrandallK. Modeltest: Testing the model of DNA substitution. Bioinformatics, 1998; 14:817–818.
28.
RambautA. FigTree: Tree Figure Drawing Tool v1.1.1., 2007.
29.
CheonisN. Dual HIV infection. Beta, 2006; 18:36–40.
30.
HemelaarJ, GouwsE, GhysPD, OsmanovS. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS, 2006; 20:W13–W23.
31.
WilliamsonC, EngelbrechtS, LambrickMet al.HIV-1 subtypes in different risk groups in South Africa. Lancet, 1995; 346:782.
32.
HuntG, TiemessenCT. Occurrence of additional NF-kappaB-binding motifs in the long terminal repeat region of South African HIV type 1 subtype C isolates. AIDS Res Hum Retroviruses, 2000; 16:305–306.
33.
NaghaviMH, SchwartzS, SonnerborgA, VahlneA. Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1. AIDS Res Hum Retroviruses, 1999; 15:1293–1303.
34.
TakebEY, KusagawaS, MotomuraK. Molecular epidemiology of HIV: Tracking AIDS pandemic. Pediatr Int, 2004; 46:236–244.
35.
deOliveira T, EngelbrechtS, van RensburgEJet al.Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: An indication of viral fitness?J Virol, 2003; 77:9422–9430.
36.
HuangDD, GleslerTA, BremerJW. Sequence characterization of the protease and partial reverse transcriptase proteins of the NED panel, and international HIV type 1 subtype reference and standards panel. AIDS Res Hum Retroviruses, 2003; 19:321–328.
37.
BallSC, AbrahaA, CollinsKRet al.Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol, 2003; 77:1021–1038.
